Article thumbnail

Profound thrombocytopenia after primary exposure to eptifibatide

By Nicholas B Norgard and Brian T Badgley


Eptifibatide is a glycoprotein IIb/IIIa receptor antagonist used to reduce the incidence of ischemic events in patients with acute coronary syndromes and those undergoing percutaneous coronary intervention. A minority of patients given eptifibatide develop acute, profound thrombocytopenia (<20,000 cells/mm3) within a few hours of receiving the drug. This case report discusses a patient who developed profound thrombocytopenia within hours of receiving eptifibatide for the first time. The Naranjo algorithm classified the likelihood that this patient’s thrombocytopenia was related to eptifibatide as probable. Profound thrombocytopenia is an uncommon but clinically important complication of eptifibatide. This case report emphasizes the importance of monitoring platelet counts routinely at baseline and within 2–6 hours of eptifibatide administration

Topics: Case Report
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther.
  2. Abciximab readministration: Results of the ReoPro Readministration Registry.
  3. Acute profound thrombocytopenia associated with readministration of eptifibatide: Case report and review of the literature.
  4. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.
  5. Association of eptifibatide and acute profound thrombocytopenia.
  6. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial experience.
  7. Delayed thrombocytopenia after treatment with abciximab: A distinct clinical entity associated with the immune response to the drug.
  8. Drug-induced immune thrombocytopenia: An overview of pathogenesis. Semin Hematol. 1999;36 Suppl 1:2–6.
  9. Drug-induced thrombocytopenia: An updated systematic review.
  10. Efficacy of abciximab readministration in coronary intervention.
  11. Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain.
  12. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated.
  13. (2000). Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment. Catheter Cardiovasc Interv.
  14. Heparin-induced thrombocytopenia: Recognition, treatment, and prevention.
  15. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy.
  16. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial.
  17. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
  18. (1998). Safe use of platelet GP IIb/IIIa inhibitors. Eur Heart J.
  19. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: Position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.
  20. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: A pooled analysis.
  21. (2000). Thrombotic thrombocytopenic purpura associated with clopidogrel.